Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Cervical Cancer

Aliases
Cervical Carcinoma, Cervix Cancer, Recurrent Cervical Carcinoma

296 clinical trials

340 products

36 drugs

1 abstract

Product
TNG260
Product
Pembrolizumab
Clinical trial
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
Status: Recruiting, Estimated PCD: 2030-04-01
Product
CTX131
Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Zimberelimab
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
AB308
Product
Durvalumab
Clinical trial
A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-03-15
Product
Paclitaxel
Product
Cisplatin
Product
Carboplatin
Product
Bevacizumab
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
Status: Active (not recruiting), Estimated PCD: 2022-10-03
Product
vudalimab
Clinical trial
A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
SGN-STNV
Clinical trial
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-01
Product
NGM831
Clinical trial
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NGM831 and NGM438 plus pembrolizumab
Product
AZD8701
Product
Recombinant Humanized Anti-PD-1 Monoclonal Antibody
Product
TransCon IL-2
Clinical trial
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2026-05-01
Product
Tebotelimab
Clinical trial
A Phase Ib/II Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Status: Recruiting, Estimated PCD: 2028-08-01
Product
SGN-ALPV
Clinical trial
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-12-13
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Status: Completed, Estimated PCD: 2023-02-08
Clinical trial
A Study of QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Status: Terminated, Estimated PCD: 2022-09-30
Product
MDX2001
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
An Open, Single-arm, Multicenter Phase II Trial of Efficacy and Safety of F520 Monotherapy in the Treatment of Advanced, Persistent, Recurrent, or Metastatic Cervical Cancer
Status: Completed, Estimated PCD: 2023-12-05
Product
Lenti-HPV-07
Clinical trial
An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants With HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
Status: Completed, Estimated PCD: 2022-06-15
Clinical trial
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Status: Recruiting, Estimated PCD: 2025-12-08
Clinical trial
A Phase I/II Clinical Trail of TC-E202 Targeting HPV16 E6 for Relapsed/Refractory to Standard Treatment or Metastatic Cervical Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Fludarabine
Product
NP137
Product
TC-E202
Product
IL-2
Product
Cyclophosphamide
Product
M7824
Product
89Zr-DFO-girentuximab
Clinical trial
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-12-01
Product
LN-145
Clinical trial
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Status: Recruiting, Estimated PCD: 2025-12-01
Product
AGEN2034
Product
AGEN1884
Product
Chemotherapy
Product
TransCon TLR7/8 Agonist
Clinical trial
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Tisotumab Vedotin
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2024-06-01
Product
margetuximab
Clinical trial
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
[225Ac]-FPI-1434
Clinical trial
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2026-04-30
Product
FPI-1547
Product
ONM-501
Product
Cemiplimab
Product
FPI-1175
Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase I/II Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of HB0028 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-05-01
Product
BA3071
Clinical trial
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Nivolumab
Product
MDNA11
Product
HB0028
Product
LN-145 + Pembrolizumab
Product
NGM831 plus Pembrolizumab
Product
XNW5004
Product
SEA-TGT
Product
sasanlimab
Product
Brentuximab vedotin
Product
QL1604
Product
ONC-392
Clinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer
Status: Completed, Estimated PCD: 2022-04-29
Product
Fludarabine + Cyclophosphamide
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of HRYZ-T101 TCR-T Cell for HPV18 Positive Advanced Solid Tumor
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-15
Product
HRYZ-T101 TCR-T Cell
Product
AN0025
Product
Cisplatin/Carboplatin
Product
XmAb®23104
Product
Yervoy
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
INCB099318
Clinical trial
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-01-30
Product
HRYZ-T101
Clinical trial
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-08-24
Clinical trial
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
KRC-01
Product
cisplatin
Product
NGM438
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 Intratumoral Injection Combined With Radiotherapy in Patients With Locally Advanced Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2027-01-30
Product
GX-188E
Clinical trial
A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients With Advanced or Recurrent, Non-resectable HPV 16-Positive Cervical Cancer
Status: Completed, Estimated PCD: 2023-11-24
Product
VB10.16
Product
Atezolizumab
Clinical trial
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Status: Active (not recruiting), Estimated PCD: 2025-01-17
Product
Placebo
Product
BL-M07D1
Product
GM103
Clinical trial
A Phase I/II, Open-label, Dose-escalation With Expansion Study of GM103 Via Intratumoral Injection, Alone and in Combination With Pembrolizumab in Adult Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-05-30
Product
GM103 and Pembrolizumab
Clinical trial
A Single-Arm, Open- Label, Multicenter Phase II Study of RC48-ADC in Combination With Zimberelimab Injection for the Treatment ,at Least First-line Platinum-containing Standard Therapy Failed in HER2-expressing Subject With Recurrent or Metastatic Cervical Cancer
Status: Recruiting, Estimated PCD: 2027-06-30
Product
Disitamab Vedotin
Product
Balstilimab
Product
Balstilimab + Zalifrelimab
Clinical trial
An Open-label, Multicenter Phase II Study Evaluating Balstilimab Alone or Balstilimab in Combination With Zalifrelimab in Patients With Advanced Cervical Cancer
Status: Withdrawn, Estimated PCD: 2024-12-30
Product
[225Ac]-FPI-1434 Injection
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Status: Recruiting, Estimated PCD: 2026-12-31
Product
CD70 CAR-T cells
Clinical trial
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
ZG005
Clinical trial
A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Status: Recruiting, Estimated PCD: 2026-05-01
Product
STK-012
Product
NBTXR3
Clinical trial
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Status: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2021-12-08
Product
Tiragolumab
Product
AZD5363
Clinical trial
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2019-04-26
Product
Brentuximab Vedotin
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
SO-C101
Clinical trial
A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-30
Product
Q702
Product
Keytruda
Clinical trial
A Multicenter, Single Arm, Open Label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-05-01
Product
MGC026
Clinical trial
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Status: Recruiting, Estimated PCD: 2026-07-01
Product
CD70 CAR-T
Product
TOS-358
Clinical trial
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
MT-8421
Clinical trial
A Two-Arm Randomized, Double-Blind, Placebo-Controlled Phase 2 Selection Trial to Evaluate the Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer Who Are Refractory to Pembrolizumab With Chemotherapy With/Without Bevacizumab.
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Product
SNS-101
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
Status: Recruiting, Estimated PCD: 2025-11-01
Product
SI-B003
Product
BL-B01D1
Product
pembrolizumab
Clinical trial
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Status: Recruiting, Estimated PCD: 2027-05-04
Product
9-valent Human Papillomavirus Recombinant Vaccine
Product
GARDASIL®
Clinical trial
A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years
Status: Recruiting, Estimated PCD: 2027-09-15
Clinical trial
A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 as a Single Agent and in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)
Status: Recruiting, Estimated PCD: 2025-10-01
Product
GI-101
Product
Lenvatinib
Product
GI-101A
Product
NGM831 plus pembrolizumab
Product
NGM831 and NGM438 plus Pembrolizumab
Clinical trial
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Product
RO7502175
Clinical trial
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-08-05
Product
KY1044
Product
KY1044 and Atezolizumab
Product
HFB200301
Product
Tislelizumab
Clinical trial
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial
Status: Recruiting, Estimated PCD: 2023-01-13
Product
9-valent HPV vaccine
Product
NGM831 + Pembrolizumab
Clinical trial
A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Avelumab
Product
TG4001
Clinical trial
A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine as Administered to 16- to 26- Year-Old Women
Status: Active (not recruiting), Estimated PCD: 2040-01-01
Product
V503
Product
GARDASIL
Product
Disitamab
Product
PRGN-2009
Clinical trial
A Randomized, Open-label, Two-arm, Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.
Status: Recruiting, Estimated PCD: 2028-01-30
Product
SHR-1316
Clinical trial
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2026-12-15
Product
Dato-DXd
Clinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
Status: Recruiting, Estimated PCD: 2027-02-19
Product
CRTE7A2-01
Clinical trial
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies
Status: Completed, Estimated PCD: 2017-01-24
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Status: Recruiting, Estimated PCD: 2023-07-24
Product
gemcitabine
Product
pemetrexed
Product
Sotatercept
Product
adavosertib
Clinical trial
A Two Part, Phase I-IIa Study Evaluating MK1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer
Status: Terminated, Estimated PCD: 2011-06-13
Product
Selinexor
Product
AGEN1884 + AGEN2034
Product
Afuresertib
Clinical trial
A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Treatment
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Docetaxel
Product
Vigil
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Product
RPTR-168
Product
FT500
Clinical trial
A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors
Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Advanced Solid Tumors or AK104 in Combination With Oxaliplatin and Capecitabine As First-line Therapy in Subjects With Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer
Status: Completed, Estimated PCD: 2022-06-16
Clinical trial
An Open Multicenter Study of the Safety, Tolerability, and Pharmacokinetics of Different Doses of Stimotimagene Copolymerplasmid at Patients With Advanced-stage Solid Tumors With Cymeven® (Ganciclovir) Infusions
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Status: Completed, Estimated PCD: 2023-02-16
Product
Ociperlimab
Clinical trial
A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)
Status: Completed, Estimated PCD: 2011-04-30
Product
NEO-201
Product
AK104
Product
XmAb®22841
Product
Investigator Choice Chemotherapy
Clinical trial
An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma
Status: Completed, Estimated PCD: 2021-03-15
Product
9-valent Human Papillomavirus
Clinical trial
A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years
Status: Completed, Estimated PCD: 2022-06-17
Product
FluBHPVE6E7
Clinical trial
Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women With NILM, ASC-US, LSIL or Low-grade CIN
Status: Recruiting, Estimated PCD: 2024-09-01
Product
bevacizumab
Clinical trial
An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Terminated, Estimated PCD: 2012-09-21
Product
²¹²Pb-DOTAM-GRPR1
Clinical trial
A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years
Status: Terminated, Estimated PCD: 2023-03-23
Clinical trial
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Terminated, Estimated PCD: 2019-07-31
Product
ADXS11-001
Clinical trial
A Phase I Clinical Study to Assess the Safety and Tolerability of CD70-targeting CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-17
Clinical trial
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-01-25
Clinical trial
A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Toripalimab
Clinical trial
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer
Status: Completed, Estimated PCD: 2022-06-15
Product
ILB-2109
Clinical trial
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Product
NGM707
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-02-06
Clinical trial
A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
An Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors
Status:
Product
Recombinant humanized anti-PD-1 monoclonal antibody
Clinical trial
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy
Status: Completed, Estimated PCD: 2022-04-05
Product
PRT1419
Product
Bintrafusp alfa
Clinical trial
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Status: Completed, Estimated PCD: 2022-01-12
Clinical trial
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-02-06
Product
ISA101b
Product
AMXT1501
Product
DFMO
Clinical trial
A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
Status: Completed, Estimated PCD: 2022-09-21
Clinical trial
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
BVAC-C
Clinical trial
Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care
Status: Completed, Estimated PCD: 2021-12-01
Product
AK112
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer: a Single-arm, Open-label Phase Ⅱ Study
Status: Withdrawn, Estimated PCD: 2025-02-01
Product
tucatinib
Product
trastuzumab
Clinical trial
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Product
VMD-928
Product
AZD5305
Product
T- Dxd
Product
Camizestrant
Product
Cisplatin + Carboplatin
Product
XmAb20717
Product
Volrustomig
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of CRTE7A2-01 TCR-T Cells in HLA-A*02:01+ Subjects With HPV16 Positive Advanced Cervical, Anal, or Head and Neck Cancers and Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Product
Sigvotatug Vedotin
Product
carboplatin
Product
Acasunlimab
Product
NC410
Product
topotecan
Product
vinorelbine
Product
irinotecan
Product
Topotecan
Product
Adavosertib
Clinical trial
A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
Status: Completed, Estimated PCD: 2022-07-15
Product
Stimotimagene copolymerplasmid
Product
Ganciclovir
Clinical trial
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Status: Completed, Estimated PCD: 2019-05-22
Clinical trial
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Status: Completed, Estimated PCD: 2020-02-06
Product
Zerun HPV-9
Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-06-01
Product
Tisotumab vedotin
Clinical trial
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Status: Terminated, Estimated PCD: 2022-09-14
Clinical trial
A Single-arm, Open, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Recurrent or Metastatic Cervical Cancer
Status: Recruiting, Estimated PCD: 2022-10-30
Clinical trial
Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years.
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Product
Gardasil 9
Product
Nab paclitaxel
Product
Sintilimab
Clinical trial
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Status: Terminated, Estimated PCD: 2019-07-09
Product
MEDI4736
Product
GLS-010
Product
paclitaxel
Product
QL1706
Product
NKTR-255
Product
Cetuximab
Product
Quadrivalent Human Papillomavirus Recombinant Vaccine
Clinical trial
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
AI-061
Clinical trial
A Phase II/III Study to Evaluate the Safety and Efficacy of BAT1308 Combined With Platinum-Based Chemotherapy ± Bevacizumab as First-Line Therapy For PD-L1-Positive (CPS ≥ 1) Persistent, Recurrent or Metastatic Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2024-04-01
Product
Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Product
RTX-321
Product
NGM707 plus Pembrolizumab
Product
RAIN-32
Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Product
N-803
Product
N-803 + Pembrolizumab + PD-L1 t-haNK
Product
A166
Product
N-803 + Pembrolizumab
Product
N-803 + Nivolumab
Product
N-803 + Atezolizumab
Product
N-803 + Avelumab
Product
QBS10072S
Product
N-803 + Nivolumab + PD-L1 t-haNK
Product
N-803 + Atezolizumab + PD-L1 t-haNK
Product
N-803 + Avelumab + PD-L1 t-haNK
Product
N-803 + Durvalumab + PD-L1 t-haNK
Product
Zirabev
Clinical trial
A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.
Status: Not yet recruiting, Estimated PCD: 2025-05-16
Clinical trial
Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Product
TQB2868
Product
Systemic Treatment
Product
AL3818
Product
Pegylated Liposomal Doxorubicin
Product
CPI-006
Clinical trial
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Status: Completed, Estimated PCD: 2022-12-28
Product
TBio-6517
Clinical trial
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-26
Product
LY4101174
Clinical trial
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Product
Artesunate
Clinical trial
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-1 Positive Cancers
Status: Recruiting, Estimated PCD: 2025-09-01
Product
KK-LC-1 TCR-T cells
Product
Aldesleukin
Clinical trial
An Observational Study to Compare Plateau Antibody Levels of a Recombinant (E.Coli) Human Papillomavirus Nonavalent (Type 6/11/16/18/31/33/45/52/58) Vaccine Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Status: Not yet recruiting, Estimated PCD: 2024-03-01
Product
Recombinant Human Papillomavirus Nonavalent Vaccine
Product
Gardasil®9
Clinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
T-VEC
Clinical trial
Cadonilimab Plus Anlotinib for Recurrent, Metastasis or Persistent Cervical Cancer
Status: Recruiting, Estimated PCD: 2025-11-30
Drug
Anlotinib
Product
Granulocyte-Macrophage Colony-Stimulating Factor
Clinical trial
Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
Status: Recruiting, Estimated PCD: 2025-10-01
Drug
Atezolizumab
Clinical trial
Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy - a Proof-of-concept Study (ALARICE Study)
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Axitinib
Clinical trial
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer (IB3, IIA2) Patients
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Platinum
Clinical trial
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery for Stage IB2-IB3 Cervical Cancer (FIGO 2018)
Status: Recruiting, Estimated PCD: 2025-12-30
Drug
Cadonilimab
Drug
AN0025
Clinical trial
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-10-01
Product
PD-1/PD-L1 Inhibitors
Clinical trial
A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HTL0039732
Clinical trial
Study on the Efficacy, Safety and Cost-effectiveness of Cadonilimab in the Treatment of Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Drug
AK104
Clinical trial
A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Status: Completed, Estimated PCD: 2020-05-12
Product
Rucaparib
Clinical trial
A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers
Status: Recruiting, Estimated PCD: 2025-01-01
Product
E7 TCR-T cells
Clinical trial
A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study ("Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)")
Status: , Estimated PCD: 2025-08-01
Product
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Product
Recombinant Human Papillomavirus Bivalent Vaccine
Clinical trial
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Product
Condironing, E7 TCR-T cells, and Aldesleukin
Clinical trial
Neoadjuvant Chemoimmunotherapy Combined With Surgery Versus Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: a Multicenter Randomized Controlled Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2031-03-01
Product
Camrelizumab
Drug
Cisplatin
Clinical trial
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-09-30
Product
VET3-TGI
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Status: Recruiting, Estimated PCD: 2025-02-24
Clinical trial
A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease
Status: Recruiting, Estimated PCD: 2024-07-01
Drug
Gemcitabine
Clinical trial
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
Status: Recruiting, Estimated PCD: 2026-05-25
Clinical trial
Phase 3 Randomized, Active-Comparator Controlled, Open-Label Trial to Evaluate the Immunogenicity & Safety of Alternate 2-Dose Regimens of Cecolin® Compared to Gardasil® in 9-14 Year-Old Girls in Low and Low-Middle Income Countries
Status: Completed, Estimated PCD: 2023-12-14
Product
Cecolin®
Product
Gardasil®
Clinical trial
Self-administered Artesunate Pessaries for Treatment of Cervical Precancer in Kenya
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
Status: Active (not recruiting), Estimated PCD: 2022-07-26
Product
NHS-IL12
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-07
Product
XB002
Clinical trial
Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Ipilimumab
Clinical trial
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Single-center, Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
DDP
Clinical trial
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
Status: Recruiting, Estimated PCD: 2026-06-01
Drug
Sacituzumab govitecan
Clinical trial
A Prospective Single Arm Trial of Concurrent Chemoradiotherapy (With Albumin-Bound Paclitaxel/Cisplatin) Followed by PD-1 Inhibitor in Locally Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Albumin-Bound Paclitaxel, cisplatin, Sintilimab
Clinical trial
Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway
Status: Active (not recruiting), Estimated PCD: 2030-11-01
Drug
pembrolizumab
Drug
olaparib
Clinical trial
Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Status: Not yet recruiting, Estimated PCD: 2026-09-30
Product
Anticoagulant
Clinical trial
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2024-02-26
Clinical trial
Evaluation of Concomitant Chemo-radiotherapy With Cisplatin vs Gemcitabine as the First Line of Treatment in Patients With Locally Advanced Cervical Cancer, With Comorbidities and Preserved Renal Function, is a Phase III Clinical Trial.
Status: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
Evaluation of Resectable Cervical Carcinoma With PET/MRI
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Gadobutrol
Clinical trial
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Window of Opportunity Trial of Fenofibrate in Patients With High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Product
Fenofibrate
Clinical trial
A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Open-Label, Single-Arm, Phase II Trial
Status: Recruiting, Estimated PCD: 2022-12-31
Clinical trial
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
Status: Active (not recruiting), Estimated PCD: 2021-02-24
Product
VX-970
Clinical trial
Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAIN
Status: Recruiting, Estimated PCD: 2024-12-31
Product
NGS analysis of ctDNA
Clinical trial
Phase II Randomized Window of Opportunity Trial of Chemoradiotherapy Alone Versus Combination With Metformin in Locally Advanced Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Drug
Metformin
Clinical trial
A Phase 1 Study Evaluating High Dose ADXS11-001 Treatment in Women With Carcinoma of the Cervix (ADXS001-07)
Status: Completed, Estimated PCD: 2017-03-08
Product
Axalimogene filolisbac
Clinical trial
A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India
Status: Completed, Estimated PCD: 2012-11-01
Product
Polymerase chain reaction
Clinical trial
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Status: Active (not recruiting), Estimated PCD: 2023-12-14
Drug
carboplatin
Drug
paclitaxel
Clinical trial
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Standard of Care PD-1 Therapy
Clinical trial
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients
Status: Completed, Estimated PCD: 2017-12-01
Drug
Tiragolumab
Clinical trial
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-30
Product
TSC-204-A0201
Product
TSC-204-C0702
Clinical trial
A Multicentre, Prospective, Randomized, Double-blind, Placebo-controlled Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Locally Advanced Cervical Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2030-04-01
Drug
Nimotuzumab
Product
Nimotuzumab
Product
TSC-203-A0201
Product
TSC-203-A0201 + TSC-201-B0702
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Adavosertib
Product
Afatinib
Product
CPI-006 + Pembrolizumab
Clinical trial
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
Status: Completed, Estimated PCD: 2022-01-20
Product
fulvestrant
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2021-11-12
Product
Enapotamab vedotin
Clinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
Status: Recruiting, Estimated PCD: 2026-03-31
Product
OC-001
Clinical trial
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-01-23
Clinical trial
FIGO 2018 Stage IB2 (> 2 to ≤4cm) Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized, Open-label Clinical Trial to Assess the Safety, Feasibility and Immunogenicity of Adjuvant PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Product
PVX7
Clinical trial
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour
Status: Active (not recruiting), Estimated PCD: 2022-04-01
Product
Durvalumab + Tremelimumab + Vinorelbine
Clinical trial
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)
Status: Not yet recruiting, Estimated PCD: 2027-08-31
Product
Dostarlimab
Drug
R-CHOP
Product
Pegylated liposomal doxorubicin
Clinical trial
Long-term Effectiveness and Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Girls Aged 9-17 Years
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
Product
Recombinant Human Papillomavirus Bivalent
Clinical trial
A Prospective, Single Arm, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104) for Newly Diagnosed Local Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2025-05-01
Drug
cyclophosphamide
Clinical trial
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
Status: Completed, Estimated PCD: 2019-10-04
Product
DPX-E7
Clinical trial
A Phase-I Study of Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NiCOL
Status: Completed, Estimated PCD: 2020-10-30
Product
Neoantigen Peptide Vaccine
Clinical trial
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-01
Product
LY4170156
Clinical trial
Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
Nicotine
Clinical trial
A Prospective Randomized Controlled Trials of Neoadjuvant Chemotherapy Combined With Serplulimab Followed by Concurrent Chemoradiation Versus Concurrent Chemoradiation Therapy Alone in Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2027-12-28
Product
Neoadjuvant Therapy
Clinical trial
Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)
Status: Terminated, Estimated PCD: 2023-12-01
Product
LITT + Pembrolizumab
Clinical trial
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Gallium Ga 68 FAPi-46
Clinical trial
A Randomized, Open Label, Phase II Trial of Anti-PD1, TSR-042, as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
TSR-042
Clinical trial
A Single-arm, Single-center, Prospective, Phase II Study of Nimotuzumab, Tislelizumab Plus Radiotherapy for Recurrent and Metastatic Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Product
Nimotuzumab、Tislelizumab
Clinical trial
Immunogenicity Non-inferiority Immuno-bridging Study of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine (E.Coli) in Healthy Population Aged 9-17 Years Old vs Aged 18-26 Years Old
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Efficacy and Safety of Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
tislelizumab
Product
PDS0101
Clinical trial
Neoadjuvant Chemotherapy Plus Camrelizumab (NACI Therapy) for Fertility Preservation in FIGO Stage IB1 Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Nab Paclitaxel
Clinical trial
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Avutometinib
Clinical trial
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Patients With High Risk of Recurrence: A Prospective, Single-Arm, Phase II Trial
Status: Recruiting, Estimated PCD: 2025-07-01
Drug
PD-1 antibody
Clinical trial
Neoadjuvant Chemotherapy Plus Camrelizumab in PD-L1-negative Locally Advanced Cervical Cancer: a Multicentre, Single-arm, Phase 2 Trial
Status: Not yet recruiting, Estimated PCD: 2025-12-31
Product
Paclitaxel-albumin
Clinical trial
Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study
Status: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
Induced and Concurrent Serplulimab Plus Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for Stage III-IVA Cervical Cancer: a Prospective, Multicenter, Randomized, Open Controlled Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2025-05-31
Product
Serplulimab
Clinical trial
A Phase 2A, Prospective, Open Label, Single Institution Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Randomized Phase II Study of Carboplatin and Paclitaxel +/- Cetuximab, in Advanced and/or Recurrent Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
cetuximab
Clinical trial
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV
Status: Recruiting, Estimated PCD: 2025-12-31
Product
5 Fluorouracil
Drug
Varlilumab
Clinical trial
Fosaprepitant Combined With Tropisetron Plus Dexamethasone in Preventing Nausea and Emesis During Fractionated Radiotherapy With Weekly Cisplatin Chemotherapy in Cervical Cancer and Nasopharyngeal Cancer
Status: Completed, Estimated PCD: 2023-07-31
Product
Fosaprepitant
Product
tropisetron
Product
Dexamethasone
Clinical trial
ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study: Safety, Toxicity and Immunological Effects of Peritumorally Delivered Immunotherapy in Early-stage Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Detection of Sentinel Lymph Nodes in Female Lower Genital Tract Cancer Patients With Contrast-Enhanced Ultrasound Imaging
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Perflubutane
Clinical trial
An Exploratory Clinical Study of Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2026-12-30
Drug
Abraxane
Clinical trial
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
Status: Recruiting, Estimated PCD: 2024-08-31
Product
NX-1607
Clinical trial
PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
Status: Active (not recruiting), Estimated PCD: 2017-01-01
Product
Gardasil
Clinical trial
Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma
Status: Completed, Estimated PCD: 2023-11-01
Product
BNT113
Product
Poly ICLC
Product
TSC-200-A0201
Clinical trial
A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
Status: Not yet recruiting, Estimated PCD: 2029-11-01
Product
UCB4594
Product
TSC-204-A0101
Product
TSC-201-B0702
Product
TSC-204-A0201 + TSC-204-A0101
Clinical trial
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer:A Multicentre, Single-arm, Phase II Trial.
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Product
TSC-200-A0201 + TSC-204-A0101
Product
TSC-200-A0201 + TSC-201-B0702
Clinical trial
A Phase I Efficacy and Safety Study of HPV16-specific Therapeutic DNA-vaccinia Vaccination in Combination With Topical Imiquimod, in Patients With HPV16+ High Grade Cervical Dysplasia (CIN3)
Status: Completed, Estimated PCD: 2023-08-01
Drug
TA-HPV
Clinical trial
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
Status: Withdrawn, Estimated PCD: 2005-12-01
Product
Tissue Repository
Clinical trial
Feasibility, Safety, and Efficacy of Concomitant Curcumin in Patients Undergoing Palliative Radiotherapy for FIGO Stage IIIB-IVA Cervical Cancer: An Open-label Pilot Trial
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Product
Curcumin
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
Spartalizumab
Clinical trial
BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."
Status: Active (not recruiting), Estimated PCD: 2021-01-01
Product
Nintedanib
Clinical trial
Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer
Status: Completed, Estimated PCD: 2023-08-11
Product
Tremelimumab
Clinical trial
A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical Trial
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Efbemalenograstim
Clinical trial
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
Status: Active (not recruiting), Estimated PCD: 2025-04-06
Product
18F-FTX
Drug
FDG
Clinical trial
Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 Trial
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Treatment Group
Clinical trial
A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-05-09
Product
De-TIL-0255
Clinical trial
Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer: a Multicenter, Single-arm, Prospective Phase II Trial
Status: Recruiting, Estimated PCD: 2023-11-30
Product
Caldonirimab and Nimotuzumab
Clinical trial
A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
Blood sample collection
Product
UCPVax
Clinical trial
A Phase II Trial of Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors in Patients With Advanced Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2025-06-30
Clinical trial
Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode
Status: Recruiting, Estimated PCD: 2034-04-30
Product
PCR and Sequence
Clinical trial
Phase III Randomized Prospective Clinical Study of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin(GP) Versus Definite Cisplatin Combined Weekly Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Gemcitabine + Cisplatin
Clinical trial
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2019-03-05
Clinical trial
Adjuvant Chemotherapy in Cell-free Human Papillomavirus Deoxyribonucleic Acid (cfHPV-DNA) Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer (CC)
Status: Not yet recruiting, Estimated PCD: 2023-10-30
Clinical trial
A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
A Single-arm Exploratory Clinical Study of Envafolimab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2027-05-31
Drug
Envafolimab
Clinical trial
Clinical Study on the Safety and Efficacy of GK01 Autologous Tumor-reactive T Cells (TRT) in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-07-19
Product
TCR T-cells
Clinical trial
ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune Response
Status: Recruiting, Estimated PCD: 2026-03-16
Product
ASTX660
Drug
mFOLFOX6
Clinical trial
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Status: Completed, Estimated PCD: 2020-10-01
Clinical trial
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-30
Product
Ipilimumab + Pembrolizumab + Durvalumab
Clinical trial
A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
Status: Completed, Estimated PCD: 2023-01-15
Product
Cabozantinib
Clinical trial
Evaluate Efficacy and Safety of Serplulimab（HLX10）in Patients With Advanced, Recurrent and Metastatic Cervical Cancer：A Prospective, Multicenter, Non-interventive Real-world Study
Status: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-10
Product
BMS-986340
Drug
Docetaxel
Clinical trial
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Status: Recruiting, Estimated PCD: 2026-06-30
Product
MGD019
Clinical trial
Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA)
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Dietary fiber capsules
Clinical trial
Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes)
Status: Active (not recruiting), Estimated PCD: 2026-05-31
Clinical trial
Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living With HIV: NECST-HIV
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
Vaccination
Product
Vaccination Provision
Product
Trilaciclib
Clinical trial
Efficacy and Safety of Trilaciclib in Myeloprotection During Chemotherapy for Advanced/Recurrent Malignant Solid Tumors - A Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Single Arm, Exploratory Clinical Study on the Neoadjuvant Treatment of Neuroendocrine Cervix Carcinoma With Camrelizumab Combined With Etoposide and Cisplatin
Status: Recruiting, Estimated PCD: 2026-08-31
Product
Karelizumab
Clinical trial
Nivolumab and Ipilimumab for Chemo-radio-immunotherapy Followed by Maintenance Therapy With Nivolumab and Ipilimumab for Primary Treatment in Locally Advanced Cervical Cancer Patients
Status: Withdrawn, Estimated PCD: 2026-06-01
Product
Pre-Chemo-radio-immunotherapy Treatment
Product
Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)
Clinical trial
Nituzumab Plus Serplulimab Combined With SBRT in Recurrent Advanced Cervical Cancer: A Prospective, Multicenter, Single-arm, Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Nituzumab
Clinical trial
Efficacy and Safety of Socazolimab Combined With Chemotherapy With or Without Bevacizumab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer: A Randomized, Double-blind, Placebo-controlled Phase III Study
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Product
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10422
Product
sintilimab
Clinical trial
Prospective Randomized Phase II Trial Comparing Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Product
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Drug
imiquimod
Clinical trial
Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Next Generation Precision Imaging for Cancer Immunotherapy: Dynamic Nuclear Polarization and Metabolomics Study
Status: Not yet recruiting, Estimated PCD: 2026-07-31
Product
Hyperpolarized 13C-Pyruvate
Clinical trial
A Phase III Multicentre Trial of Weekly Induction Chemotherapy Followed by Standard Chemoradiation Versus Standard Chemoradiation Alone in Patients With Locally Advanced Cervical Cancer
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Product
Binimetinib
Product
Capivasertib
Clinical trial
Neoadjuvant Chemotherapy Combined With PD-1 Antibody + Radical Radiotherapy in Unresectable Locally Advanced Cervical Cancer Patients
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Refractory or Relapsed Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-21
Product
CHT101
Clinical trial
Phase II Trial of Hypofractionated Radiochemotherapy for Women With Metastatic or Bulky Uterine Cervix Cancer
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Multicenter, Pilot Study Evaluating Immune Impact and Safety of Nivolumab in Combination With Ipilimumab (Immune Combination) Before Initial RT-CT Treatment for Cervix Cancer.: the French GINECO - COLIBRI Study
Status: Active (not recruiting), Estimated PCD: 2021-08-30
Product
Nivolumab + Ipilimumab
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
AB598
Clinical trial
Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Status: Terminated, Estimated PCD: 2023-01-30
Product
Pemetrexed
Drug
fluorouracil
Clinical trial
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2030-10-07
Product
Telaglenastat
Clinical trial
Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)
Status: Recruiting, Estimated PCD: 2025-07-01
Product
dostarlimab
Clinical trial
Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines
Status: Terminated, Estimated PCD: 2011-12-31
Drug
64Cu-ATSM
Clinical trial
A Controlled Clinical Study of Envafolimab (PD-L1 Antibody) Subcutaneous Injection Combined With Endostar and Concurrent Chemoradiotherapy in Treatment of Locally Advanced Primary Cervical Cancer
Status: Not yet recruiting, Estimated PCD: 2024-05-16
Drug
cis-platinum
Product
Envafolimab
Product
Recombinant Human Endostatin
Clinical trial
A Multicenter, Open-label, Phase II Study of AK104（an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer
Status: Completed, Estimated PCD: 2024-02-28
Clinical trial
Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial ("Puente de Respuesta Inmunológica Para Mejorar el Acceso a Vacunas y ERrAdicar el Cancer")
Status: Active (not recruiting), Estimated PCD: 2022-09-30
Clinical trial
A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years
Status: Active (not recruiting), Estimated PCD: 2027-12-31
Product
Nonavalent HPV vaccine
Product
Bivalent HPV vaccine
Clinical trial
A First-in-human Phase I Two-stage Clinical Trial for Intratumoral Injection of Recombinant Oncolytic Type II Herpes Simplex Virus (BS-006) in Patients With Recurrent Cervical Cancer
Status: Recruiting, Estimated PCD: 2023-12-31
Product
BS-006
Clinical trial
Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Loperamide
Clinical trial
Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study
Status: Recruiting, Estimated PCD: 2023-12-14
Product
Concurrent Chemotherapy
Clinical trial
A Phase 2 Study of Dostarlimab in Combination With Cobolimab in Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Cobolimab
Clinical trial
Phase 1 2 Study of Individualized Bone Marrow Sparing Image Guided Radiotherapy Incorporating Novel Use of Granulocyte Colony Stimulating Factor and FDG PET Imaging
Status: Recruiting, Estimated PCD: 2025-05-01
Drug
GCSF
Clinical trial
Phase II Trial of M7824 in Subjects With HPV Associated Malignancies
Status: Completed, Estimated PCD: 2021-02-02
Clinical trial
Precision Medicine Imaging for Cervical Cancer: Integrating MR Fingerprinting, Dynamic Nuclear Polarization (DNP)-MRI and Artificial Intelligence Radiomics
Status: Recruiting, Estimated PCD: 2024-07-31
Product
Hyperpolarized 13C Pyruvate
Clinical trial
HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HMBD-001
Clinical trial
Study of Pd-1 Antibody in Combination With Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
Status: Recruiting, Estimated PCD: 2023-10-01
Product
Cisplatin + Albumin-bound Paclitaxel + PD-1 Monoclonal Antibody
Clinical trial
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2033-11-01
Clinical trial
Neoadjuvant Chemotherapy Plus Cadunilizumab Followed by Extrafascial Hysterectomy for FIGO Stage IB2 Cervical Cancer: a Multicenter, Single-arm, Phase 2 Trial.
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer: a Randomized Prospective Study (PROVIDENCE Trial)
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Product
Multimodal intervention on sexual dysfunction and quality-of-life
Clinical trial
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-07-31
Drug
INCB099280
Clinical trial
A Prospective Randomized Controlled Trial for Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy in the Treatment of Advanced Cervical Cancer at 2018 FIGO Staging
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Single-arm, Open-label, Multicenter Phase II Study of Cadonilimab Combined With Nab -Paclitaxel in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Previously Treated With Immune Checkpoint Inhibitors
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Status: , Estimated PCD: 2025-04-01
Clinical trial
Toripalimab Combined With Definitive Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma Patients
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
Toripalimab Combined With Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for High-risk Locally Advanced Cervical Cancer: the Phase II Single-arm TorCH -CC Study
Status: Recruiting, Estimated PCD: 2026-05-01
Product
TSC-204
Product
TSC-204-C0702 + TSC-203-A0201
Clinical trial
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
PHN-010
Product
Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab
Clinical trial
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
LY4052031
Clinical trial
Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
Status: Completed, Estimated PCD: 2024-06-17
Product
Sindilimab + Paclitaxel + Cisplatin